Chemistry:EXS4318

From HandWiki

EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb.[1][2] In 2023, it entered clinical trials in humans.[3]

References

  1. ↑ Philippidis, Alex (1 January 2023). "BMS Collaboration Paying Off for Exscientia: AI drug developer designs EXS4318, the I&I small molecule that has entered Phase I trials overseen by pharma giant in up-to-$1.3B+ partnership". GEN Edge 5 (1): 147–150. doi:10.1089/genedge.5.1.31. 
  2. ↑ Arnold, Carrie (1 June 2023). "Inside the nascent industry of AI-designed drugs" (in en). Nature Medicine 29 (6): 1292–1295. doi:10.1038/s41591-023-02361-0. ISSN 1546-170X. https://www.nature.com/articles/s41591-023-02361-0. 
  3. ↑ "BMS in-licensed PKC theta inhibitor enters clinical trials" (in en). https://www.europeanpharmaceuticalreview.com/news/179265/bms-in-licensed-pkc-theta-inhibitor-enters-clinical-trials/. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:EXS4318&oldid=3328710"